Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

Accelerating precision oncology by converging pragmatic trials and real-world evidence

Engaging sufficient numbers of patients with cancers that have particular molecular characteristics is a key challenge in building evidence to support precision medicine in oncology. These challenges could be addressed by converging pragmatic clinical trials and hospital cancer informatics infrastructures to integrate cancer care and research.
By
  1. Kjetil Taskén

    1. Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

  2. Piers Mahon

    1. DIGICORE, Fondation Universitaire, Brussels, Belgium.

Access through your institution
Buy or subscribe

Introduction

Access options

Access through your institution

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41573-025-00047-5

Acknowledgements

The European DRUP-like trial collaboration is supported by “Precision Cancer Medicine for all EU Citizens” (PCM4EU), funded by the EU4Health programme as part of Europe’s Beating Cancer Plan (grant: 101079984) and “Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials” (PRIME-ROSE coordinated by K.T.), funded under the Horizon Europe programme (grant: 101104269). DigiONE is supported IQVIA and Illumina, and ERDF Interregional Innovation Investment Instrument (grant: 10115081).

Peer review information

Nature Reviews Drug Discovery thanks H. Moses and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

References

  1. van der Velden, D. L. et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature 574, 127–131 (2019).

    Article  PubMed  Google Scholar 

  2. Taskén, K. et al. PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe. Acta Oncol. 63, 385–391 (2024).

    Article  PubMed  Google Scholar 

  3. Mahon, P. et al. A federated learning system for precision oncology in Europe: DigiONE. Nat. Med. 30, 334–337 (2024).

    Article  PubMed  Google Scholar 

  4. Kessels, R. et al. The Trial within Cohorts (TwiCs) study design in oncology: experience and methodological reflections. BMC Med. Res. Methodol. 23, 117 (2023).

    Article  PubMed  Google Scholar 

  5. Primakov, S. et al. Automated detection and segmentation of non-small cell lung cancer computed tomography images. Nat. Commun. 13, 3423 (2022).

    Article  PubMed  Google Scholar 

  6. Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210–216 (2019).

    Article  PubMed  Google Scholar 

Download references

Supplementary Information

  1. Supplementary information

Competing Interests

The authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links